Windlas Biotech Submits Q4 FY26 Certificate Under SEBI Depositories Regulations
Windlas Biotech Limited submitted its Q4 FY26 certificate under SEBI Depositories Regulations on April 6, 2026. The certificate from MUFG Intime India Private Limited confirmed no demat requests were received during the quarter ended March 31, 2026, as the company has no physical shares outstanding.

*this image is generated using AI for illustrative purposes only.
Windlas biotech Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE and NSE on April 6, 2026.
Quarterly Compliance Certificate Details
The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The document pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
| Parameter: | Details |
|---|---|
| Quarter Period: | March 31, 2026 |
| Certificate Date: | April 03, 2026 |
| Filing Date: | April 06, 2026 |
| Registrar: | MUFG Intime India Private Limited |
Key Confirmation
MUFG Intime India Private Limited confirmed that during the quarter ended March 31, 2026, no demat requests were received for processing. The registrar specifically noted that Windlas Biotech Limited does not have any physical shares outstanding, indicating that all shares are already in dematerialized form.
Regulatory Compliance
The submission was made to the compliance departments of both major Indian stock exchanges. Company Secretary and Compliance Officer Ananta Narayan Panda signed the filing letter, ensuring adherence to regulatory requirements. This quarterly certificate filing is a standard compliance requirement for listed companies under SEBI regulations.
Company Information
Windlas Biotech Limited operates from its registered office in Dehradun, Uttarakhand, with its corporate office located in Gurgaon, Haryana. The company maintains its listing on both BSE and NSE, trading under the symbols 543329 and WINDLAS respectively.
How might Windlas Biotech's complete dematerialization of shares impact its future capital raising activities and investor accessibility?
What strategic initiatives is Windlas Biotech likely to pursue in the pharmaceutical sector following this clean compliance record?
Will the transition from Link Intime to MUFG Intime as registrar bring enhanced digital services or operational efficiencies for shareholders?

































